Metobeta (Metoprolol Tartrate)

Metoprolol tartrate selectively blocks β1‑adrenergic receptors in the heart. By preventing catecholamines from binding, it slows the heart rate, reduces the force of contraction, and lowers cardiac output. This results in decreased arterial pressure and reduced myocardial oxygen demand, which are beneficial in hypertension, angina, and heart failure.

The appropriate dose of Metobeta is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and any co‑existing health issues. Dosage may be started low and adjusted gradually; patients should follow the specific instructions provided by their healthcare professional.

Safety data for metoprolol tartrate in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate each case individually and discuss alternatives when appropriate.

To request Metobeta, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metobeta (metoprolol tartrate) is a cardio‑selective β1‑blocker, offering a favorable profile for patients with hypertension, angina, or heart failure. Compared with non‑selective beta blockers, it has a lower risk of bronchospasm in patients with respiratory disease, while still providing effective heart rate control.

Metobeta should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight, and heat sources to maintain stability and potency throughout its shelf life.

Metobeta is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescribing clinician’s guidance on timing and whether to split or crush tablets, if applicable.

Serious risks include severe bradycardia, heart block, marked hypotension, bronchospasm in susceptible individuals, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, extreme fatigue, difficulty breathing, or swelling of the face or throat.

Metobeta is contraindicated in patients with known hypersensitivity to metoprolol or other beta blockers, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and individuals experiencing uncompensated heart failure or cardiogenic shock. Clinicians must assess each patient’s medical history before prescribing.